Jonathan A Ledermann

Niraparib Maintenance Therapy in Platinum-Sensitive, Recurrent Ovarian Cancer.

Ignace Vergote, Christian Marth, Sven Mahner, 2016, The New England journal of medicine.

A phase 3 trial of bevacizumab in ovarian cancer.

Jacobus Pfisterer, Jalid Sehouli, Rainer Kimmig, 2011, The New England journal of medicine.

Cdc7 Kinase Is a Predictor of Survival and a Novel Therapeutic Target in Epithelial Ovarian Carcinoma

Kai Stoeber, Gareth H Williams, Mohammed Rashid, 2009, Clinical Cancer Research.

Homologous recombination deficiency and ovarian cancer.

Y. Drew, J. Ledermann, R. Kristeleit, 2016, European journal of cancer.

Olaparib tablets as maintenance therapy in patients with platinum-sensitive, relapsed ovarian cancer and a BRCA1/2 mutation (SOLO2/ENGOT-Ov21): a double-blind, randomised, placebo-controlled, phase 3 trial.

Val Gebski, Philipp Harter, Tomasz Huzarski, 2017, The Lancet. Oncology.

Different strategies of sequential and combination chemotherapy for patients with poor prognosis advanced colorectal cancer (MRC FOCUS): a randomised controlled trial

Richard J Stephens, Mahesh KB Parmar, M. Parmar, 2007, The Lancet.

Standard chemotherapy with or without bevacizumab for women with newly diagnosed ovarian cancer (ICON7): overall survival results of a phase 3 randomised trial

Jacobus Pfisterer, Gordon C Jayson, Michael Quinn, 2015, The Lancet. Oncology.

Ovarian cancer

Henry C Kitchener, Gordon C Jayson, E. Kohn, 2014, The Lancet.